Duyuru • Apr 02
TherapeuticsMD, Inc. announced delayed annual 10-K filing On 04/01/2026, TherapeuticsMD, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Reported Earnings • Mar 31
Full year 2025 earnings released: US$0.056 loss per share (vs US$0.20 loss in FY 2024) Full year 2025 results: US$0.056 loss per share (improved from US$0.20 loss in FY 2024). Revenue: US$3.02m (up 72% from FY 2024). Net loss: US$653.0k (loss narrowed 72% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. New Risk • Jan 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (US$25.9m market cap). Reported Earnings • Nov 14
Third quarter 2025 earnings released: EPS: US$0.004 (vs US$0.049 loss in 3Q 2024) Third quarter 2025 results: EPS: US$0.004 (up from US$0.049 loss in 3Q 2024). Revenue: US$784.0k (up 43% from 3Q 2024). Net income: US$50.0k (up US$617.0k from 3Q 2024). Profit margin: 6.4% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. Duyuru • Nov 04
TherapeuticsMD, Inc., Annual General Meeting, Dec 15, 2025 TherapeuticsMD, Inc., Annual General Meeting, Dec 15, 2025. Board Change • Sep 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Justin Roberts was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 18
Second quarter 2025 earnings released: EPS: US$0.047 (vs US$0.091 loss in 2Q 2024) Second quarter 2025 results: EPS: US$0.047 (up from US$0.091 loss in 2Q 2024). Net income: US$545.0k (up US$1.60m from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings. Duyuru • Jun 03
Mayne Pharma LLC Provides Update on Legal Proceeding with TherapeuticsMD, Inc Mayne Pharma Group Limited announced that one of its US subsidiaries, Mayne Pharma LLC, has filed a complaint in the United States District Court for the District of Delaware against TherapeuticsMD, Inc. This complaint is related to the legal proceeding brought by TXMD which was previously disclosed in Mayne Pharma's ASX announcement on 11 April 2025. Mayne Pharma's complaint asserts claims against TXMD for breach of contract and fraud based on allegations that TXMD concealed information about certain commercialisation assets it sold to Mayne Pharma on 4 December 2022. Mayne Pharma is seeking more than $11.5 million in damages it incurred as a result of TXMD's alleged misrepresentations about the assets. In addition to filing a complaint against TXMD, Mayne Pharma has filed a motion to dismiss TXMD's proceeding in its entirety. Mayne Pharma emphatically denies any and all allegations of wrongdoing and believes TXMD's proceeding to be without merit, but there is no assurance that Mayne Pharma would be successful in any defence thereof. Reported Earnings • May 15
First quarter 2025 earnings released: US$0.055 loss per share (vs US$0.07 loss in 1Q 2024) First quarter 2025 results: US$0.055 loss per share (improved from US$0.07 loss in 1Q 2024). Net loss: US$636.0k (loss narrowed 21% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 28
Full year 2024 earnings released: US$0.20 loss per share (vs US$0.74 loss in FY 2023) Full year 2024 results: US$0.20 loss per share (improved from US$0.74 loss in FY 2023). Net loss: US$2.31m (loss narrowed 70% from FY 2023). New Risk • Feb 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.86m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Market cap is less than US$10m (US$9.86m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue). New Risk • Jan 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (US$9.92m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue). New Risk • Jan 02
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.92m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$9.92m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue). Reported Earnings • Nov 14
Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023) Third quarter 2024 results: US$0.049 loss per share (improved from US$0.13 loss in 3Q 2023). Net loss: US$567.0k (loss narrowed 61% from 3Q 2023). Duyuru • Sep 23
TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024 TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024. Reported Earnings • Aug 14
Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023) Second quarter 2024 results: US$0.091 loss per share (improved from US$0.24 loss in 2Q 2023). Net loss: US$1.05m (loss narrowed 56% from 2Q 2023). Duyuru • Aug 19
TherapeuticsMD, Inc. Announces Executive Changes TherapeuticsMD, Inc. announced that on August 17, 2023, Mr. Michael C. Donegan, the Principal Financial and Accounting Officer of the company, notified the Company of his decision to resign from such positions, effective as of August 17, 2023. Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the effective date of Mr. Donegan’s resignation. Mr. Ziegler, age 50, has served as founder and chief executive officer of JZ Advisory Group, a consulting company largely focused on providing fractional CFO and outsourced accounting services to middle-market and entrepreneurial businesses, since January 2022. He previously served as the Chief Financial Officer of DAS Health, a private equity owned provider of IT Services to healthcare providers, from April 2021 to December 2021 and as the Chief Financial Officer of Encompass Onsite, a provider of end-to-end property solutions, from November 2018 to February 2021. Prior to joining Encompass, he held multiple roles as a CFO in the healthcare industry, including private equity backed specialty pharmacy Biomatrix and Novis Pharmaceuticals. Mr. Ziegler has been a director of Progressive Care Inc. since December 2021. He earned his B.S. in Finance and an M.B.A. from Florida Atlantic University. Duyuru • May 19
TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023 TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023, at 08:00 US Eastern Standard Time. Agenda: To consider and discuss the election of directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified; to approve the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2022; to approve an amendment to increase the number of authorized shares of common stock; to approve the issuance of up to 5,000,000 shares of the Company’s common stock to be sold in one or more private placements to Rubric Capital Management LP or one or more of its affiliates, under a subscription agreement with Rubric; to ratify the appointment of Grant Thornton LLP as the independent auditor of Company for the fiscal year ending December 31, 2023; and to discuss other business matters. Major Estimate Revision • May 23
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$114.0m to US$111.0m. 2022 losses expected to reduce from -US$32.50 to -US$7.50 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$87.50 to US$2.50. Share price fell 18% to US$2.56 over the past week. Major Estimate Revision • May 07
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.16 to -US$0.65 per share. Revenue forecast of US$113.9m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 4.8% next year. Consensus price target down from US$4.17 to US$1.75. Share price fell 24% to US$0.15 over the past week. Price Target Changed • May 06
Price target decreased to US$3.75 Down from US$4.33, the current price target is an average from 3 analysts. New target price is 2,346% above last closing price of US$0.15. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.43 last year. Recent Insider Transactions Derivative • Apr 28
Co-Founder notifies of intention to sell stock Robert Finizio intends to sell 10m shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of April. If the sale is conducted around the recent share price of US$0.24, it would amount to US$2.4m. Since June 2021, Robert has owned 19.99m shares directly. Company insiders have collectively bought US$1.1m more than they sold, via options and on-market transactions, in the last 12 months. Breakeven Date Change • Apr 27
Forecast breakeven date pushed back to 2024 The 3 analysts covering TherapeuticsMD previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 88% per year to 2023. The company is expected to make a profit of US$43.7m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule. Recent Insider Transactions Derivative • Mar 22
Co-Founder notifies of intention to sell stock Robert Finizio intends to sell 5m shares in the next 90 days after lodging an Intent To Sell Form on the 17th of March. If the sale is conducted around the recent share price of US$0.36, it would amount to US$1.8m. Since March 2021, Robert's direct individual holding has increased from 19.90m shares to 19.99m. Company insiders have collectively bought US$1.1m more than they sold, via options and on-market transactions, in the last 12 months. Major Estimate Revision • Mar 17
Consensus revenue estimates fall by 24% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$150.4m to US$114.0m. Forecast losses increased from -US$0.15 to -US$0.16 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$4.33 to US$4.17. Share price fell 8.8% to US$0.36 over the past week. Breakeven Date Change • Mar 13
Forecast breakeven date pushed back to 2024 The 3 analysts covering TherapeuticsMD previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 88% per year to 2023. The company is expected to make a profit of US$43.7m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule. Reported Earnings • Mar 11
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: US$0.43 loss per share (up from US$0.67 loss in FY 2020). Revenue: US$87.0m (up 34% from FY 2020). Net loss: US$172.4m (loss narrowed 6.1% from FY 2020). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 73%, compared to a 20% growth forecast for the pharmaceuticals industry in the US. Recent Insider Transactions • Nov 24
Independent Director recently bought US$579k worth of stock On the 18th of November, Cooper Collins bought around 1m shares on-market at roughly US$0.58 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$1.4m more in shares than they have sold in the last 12 months. Reported Earnings • Nov 13
Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020) The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$25.4m (up 31% from 3Q 2020). Net loss: US$47.4m (loss widened 45% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Breakeven Date Change • Nov 13
Forecast to breakeven in 2023 The 4 analysts covering TherapeuticsMD expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$18.9m in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule. Executive Departure • Oct 06
Executive Vice President of Operations Edward Borkowski has left the company On the 30th of September, Edward Borkowski's tenure as Executive Vice President of Operations ended after 1.7 years in the role. As of June 2021, Edward still personally held 59.25k shares (US$71k worth at the time). Edward is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.67 years. Recent Insider Transactions • Aug 20
Independent Director recently bought US$725k worth of stock On the 18th of August, Cooper Collins bought around 1m shares on-market at roughly US$0.72 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$804k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 05
Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$23.0m (up 115% from 2Q 2020). Net loss: US$42.7m (loss narrowed 18% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Breakeven Date Change • Aug 05
No longer forecast to breakeven The 4 analysts covering TherapeuticsMD no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$45.5m in 2023. New consensus forecast suggests the company will make a loss of US$10.1m in 2023. Recent Insider Transactions Derivative • May 15
Co-Founder exercised options and sold US$70k worth of stock On the 11th of May, Robert Finizio exercised options to acquire 68k shares at no cost and sold these for an average price of US$1.04 per share. This trade did not impact their existing holding. For the year to December 2020, Robert's total compensation was 22% salary and 78% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2020, Robert's direct individual holding has decreased from 20.40m shares to 19.90m. Company insiders have collectively bought US$85k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • May 06
First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$19.9m (up 62% from 1Q 2020). Net loss: US$39.4m (loss narrowed 31% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Analyst Estimate Surprise Post Earnings • Mar 04
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Over the next year, revenue is forecast to grow 59%, compared to a 27% growth forecast for the Pharmaceuticals industry in the US. Reported Earnings • Mar 04
Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$64.9m (up 31% from FY 2019). Net loss: US$183.5m (loss widened 4.2% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. Price Target Changed • Feb 04
Price target raised to US$8.00 Up from US$6.40, the current price target is an average from 6 analysts. The new target price is 373% above the current share price of US$1.69. As of last close, the stock is down 34% over the past year. Is New 90 Day High Low • Jan 26
New 90-day high: US$1.61 The company is up 17% from its price of US$1.38 on 27 October 2020. The American market is also up 17% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$25.24 per share. Is New 90 Day High Low • Dec 09
New 90-day low: US$1.21 The company is down 10.0% from its price of US$1.34 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$20.91 per share. Price Target Changed • Dec 06
Price target raised to US$8.20 Up from US$7.28, the current price target is an average from 8 analysts. The new target price is 521% above the current share price of US$1.32. As of last close, the stock is down 46% over the past year. Analyst Estimate Surprise Post Earnings • Nov 11
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 126%, compared to a 22% growth forecast for the Pharmaceuticals industry in the US. Reported Earnings • Nov 11
Third quarter 2020 earnings released: US$0.12 loss per share The company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$19.3m (down 19% from 3Q 2019). Net loss: US$32.6m (loss widened 2.0% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Oct 31
New 90-day low: US$1.22 The company is down 34% from its price of US$1.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$9.19 per share.